Live | Norge | Sverige | Danmark | Europa | USA | Valuta | Råvaror | OTC-marknad | NDXFördröjda kurser. Senast uppdaterad: fredag 20. april
Översikt
Kurslista
Index
Nyheter
Största transaktioner
Teckningsrätter
Historik
Vinnare/förlorare
Hög/låg

17/04-2018 08:30:00: (BIOVIC-B.ST) Positive results with DiviTum® from new Pfizer study presented at the AACR congress

Uppsala, Sweden, 2018-04-17, New results from a Pfizer study on Ibrance® (palbociclib, Pfizer) of women with metastatic breast cancer demonstrate that DiviTum can provide fast evaluation of biologic effect demonstrating CDK 4/6 inhibition.

The study, presented at the ongoing AACR congress in Chicago, concluded that using DiviTum to measure cell proliferation in blood samples could potentially be used to assess cell cycle modulation by Ibrance®.

"We are pleased that DiviTum is included by Pfizer in their clinical development of Ibrance®. These positive results are in line with previously presented DiviTum data evaluating biologic effect of demonstrating CDK 4/6 inhibition in connection with treatment of breast cancer. The results take us yet another step closer to our vision of enabling the best possible treatment for cancer patients from day one" says Anders Rylander, CEO Biovica. 

Study ref. NCT02499146
http://www.abstractsonline.com/pp8/#!/4562/presentation/11185
https://congress-download.pfizer.com/Assets/Templates/file_pdf.aspx?docId=1743&c=1

More information:
Anders Rylander, CEO Biovica.
Phone: +46 (0)18 444 48 35,
E-mail: anders.rylander@biovica.com

This information is information that Biovica International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person(s) set out above, at 08.30 CET on April 17, 2018.

About Biovica

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company's DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.

Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB.

Read more: www.biovica.com

Extern länk:http://news.cision.com/biovica-international-ab/r/positive-results-with-divitum--from-new-pfizer-study-presented-at-the-aacr-congress,c2497168
Extern länk:http://mb.cision.com/Main/14910/2497168/823324.pdf
Extern länk:http://news.cision.com/biovica-international-ab/i/posteraacr,c2388707

Nyheten är levererad av Cision

Utformning |  Hjälp |  Utskrift  | Byt till realtid  Öppna marknader: Oslo Børs, Stockholm, København fondsbørs, Unoterte Norge
fredag 20/04-2018 14:54:46